The expert explained the rationale for the phase I first-in-human clinical trial evaluating the combination of a gamma-secretase inhibitor and B-cell maturation antigen CAR T-cells in patients with heavily pretreated multiple myeloma.
Andrew J. Cowan, MD
Advertisement
Articles by Andrew J. Cowan, MD
Andrew J. Cowan, MD, discusses efficacy and safety of BCMA CAR T-cell therapy in patients with relapsed/refractory multiple myeloma.
Advertisement
Latest Updated Articles
Andrew J. Cowan, MD, Discusses the Phase I Clinical Trial of GSI and BCMA CAR T-CellsPublished: February 17th 2020 | Updated:
Dr. Cowan on Efficacy and Safety of BCMA CAR T-Cells in Multiple MyelomaPublished: January 29th 2020 | Updated:
Advertisement
Advertisement
Trending on CGTlive®
1
CGTLive®’s Weekly Rewind – October 24, 2025
2
Guess the Therapy Answer October 23, 2025
3
CARsgen’s CAR-T Satri-Cel Significantly Reduces CA19-9 Levels in Patients With Pancreatic Ductal Adenocarcinoma
4
